Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, J.M. Ferrero-Cafiero et al.|Nature Communications|2024Cited by 23
124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trialMafalda Oliveira, Aleix Prat, Tomás Pascual et al.|ESMO Open|2023Cited by 8
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXdChristian F. Singer, Angelika Pichler, Georg Pfeiler et al.|癌症：英文版|2025Cited by 3
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trialFara Brasó‐Maristany, Aleix Prat, Mafalda Oliveira et al.|ESMO Open|2023Cited by 0